3D Skeletal Uptake of F Sodium Fluoride in PET/CT Images is Associated with Overall Survival in Patients with Prostate Cancer

Overview

Journal EJNMMI Res

Date 2017 Feb 18

PMID 28210997

Citations 15

Authors

Sarah Lindgren Belal

May Sadik

Reza Kaboteh

Nezar Hasani

Olof Enqvist

Linus Svarm

Fredrik Kahl

Jane Simonsen

Mads H Poulsen

Mattias Ohlsson

Poul F Hoilund-Carlsen

Lars Edenbrandt

Elin Tragardh

Affiliations

Soon will be listed here.

Abstract

Background: Sodium fluoride (NaF) positron emission tomography combined with computer tomography (PET/CT) has shown to be more sensitive than the whole-body bone scan in the detection of skeletal uptake due to metastases in prostate cancer. We aimed to calculate a 3D index for NaF PET/CT and investigate its correlation to the bone scan index (BSI) and overall survival (OS) in a group of patients with prostate cancer.

Methods: NaF PET/CT and bone scans were studied in 48 patients with prostate cancer. Automated segmentation of the thoracic and lumbar spines, sacrum, pelvis, ribs, scapulae, clavicles, and sternum were made in the CT images. Hotspots in the PET images were selected using both a manual and an automated method. The volume of each hotspot localized in the skeleton in the corresponding CT image was calculated. Two PET/CT indices, based on manual (manual PET index) and automatic segmenting using a threshold of SUV 15 (automated PET index), were calculated by dividing the sum of all hotspot volumes with the volume of all segmented bones. BSI values were obtained using a software for automated calculations.

Results: BSI, manual PET index, and automated PET index were all significantly associated with OS and concordance indices were 0.68, 0.69, and 0.70, respectively. The median BSI was 0.39 and patients with a BSI >0.39 had a significantly shorter median survival time than patients with a BSI <0.39 (2.3 years vs not reached after 5 years of follow-up [p = 0.01]). The median manual PET index was 0.53 and patients with a manual PET index >0.53 had a significantly shorter median survival time than patients with a manual PET index <0.53 (2.5 years vs not reached after 5 years of follow-up [p < 0.001]). The median automated PET index was 0.11 and patients with an automated PET index >0.11 had a significantly shorter median survival time than patients with an automated PET index <0.11 (2.3 years vs not reached after 5 years of follow-up [p < 0.001]).

Conclusions: PET/CT indices based on NaF PET/CT are correlated to BSI and significantly associated with overall survival in patients with prostate cancer.

Citing Articles

Deep Learning-Based Detection and Classification of Bone Lesions on Staging Computed Tomography in Prostate Cancer: A Development Study.

Belue M, Harmon S, Yang D, An J, Gaur S, Law Y Acad Radiol. 2024; 31(6):2424-2433.

PMID: 38262813 PMC: 11214604. DOI: 10.1016/j.acra.2024.01.009.

Applications of artificial intelligence in orthopaedic surgery.

Farhadi F, Barnes M, Sugito H, Sin J, Henderson E, Levy J Front Med Technol. 2023; 4:995526.

PMID: 36590152 PMC: 9797865. DOI: 10.3389/fmedt.2022.995526.

Freely Available, Fully Automated AI-Based Analysis of Primary Tumour and Metastases of Prostate Cancer in Whole-Body [F]-PSMA-1007 PET-CT.

Tragardh E, Enqvist O, Ulen J, Jogi J, Bitzen U, Hedeer F Diagnostics (Basel). 2022; 12(9).

PMID: 36140502 PMC: 9497460. DOI: 10.3390/diagnostics12092101.

Post-reconstruction enhancement of [F]FDG PET images with a convolutional neural network.

Ly J, Minarik D, Jogi J, Wollmer P, Tragardh E EJNMMI Res. 2021; 11(1):48.

PMID: 33974171 PMC: 8113431. DOI: 10.1186/s13550-021-00788-5.

RECOMIA-a cloud-based platform for artificial intelligence research in nuclear medicine and radiology.

Tragardh E, Borrelli P, Kaboteh R, Gillberg T, Ulen J, Enqvist O EJNMMI Phys. 2020; 7(1):51.

PMID: 32754893 PMC: 7403290. DOI: 10.1186/s40658-020-00316-9.

References

Apolo A, Lindenberg L, Shih J, Mena E, Kim J, Park J . Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. J Nucl Med. 2016; 57(6):886-92. PMC: 6599519. DOI: 10.2967/jnumed.115.166512. View

Anand A, Morris M, Kaboteh R, Bath L, Sadik M, Gjertsson P . Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. J Nucl Med. 2015; 57(1):41-5. PMC: 4975929. DOI: 10.2967/jnumed.115.160085. View

Lin C, Bradshaw T, Perk T, Harmon S, Eickhoff J, Jallow N . Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. J Nucl Med. 2016; 57(12):1872-1879. PMC: 6952054. DOI: 10.2967/jnumed.116.177295. View

Reza M, Bjartell A, Ohlsson M, Kaboteh R, Wollmer P, Edenbrandt L . Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy. EJNMMI Res. 2014; 4:58. PMC: 4205473. DOI: 10.1186/s13550-014-0058-y. View

Meirelles G, Schoder H, Ravizzini G, Gonen M, Fox J, Humm J . Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010; 16(24):6093-9. PMC: 3402086. DOI: 10.1158/1078-0432.CCR-10-1357. View

Caglar M, Kupik O, Karabulut E, Hoilund-Carlsen P . Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?. Rev Esp Med Nucl Imagen Mol. 2015; 35(1):3-11. DOI: 10.1016/j.remn.2015.08.006. View

Ulmert D, Solnes L, Thorek D . Contemporary approaches for imaging skeletal metastasis. Bone Res. 2015; 3:15024. PMC: 4502405. DOI: 10.1038/boneres.2015.24. View

Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G . A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?. Bioinformatics. 2008; 24(19):2200-8. PMC: 2553442. DOI: 10.1093/bioinformatics/btn374. View

Top A, Hamarneh G, Abugharbieh R . Active learning for interactive 3D image segmentation. Med Image Comput Comput Assist Interv. 2011; 14(Pt 3):603-10. DOI: 10.1007/978-3-642-23626-6_74. View

10.

Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber J . Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice. Eur Urol Focus. 2017; 2(5):540-546. DOI: 10.1016/j.euf.2016.02.013. View

11.

Kaboteh R, Damber J, Gjertsson P, Hoglund P, Lomsky M, Ohlsson M . Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res. 2013; 3(1):9. PMC: 3570487. DOI: 10.1186/2191-219X-3-9. View

12.

Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi J, Kondo K . Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC Cancer. 2016; 16:128. PMC: 4759962. DOI: 10.1186/s12885-016-2176-6. View

13.

Aydin A, Yu J, Zhuang H, Alavi A . Detection of bone marrow metastases by FDG-PET and missed by bone scintigraphy in widespread melanoma. Clin Nucl Med. 2005; 30(9):606-7. DOI: 10.1097/01.rlu.0000174200.67064.28. View

14.

Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View

15.

Wakabayashi H, Nakajima K, Mizokami A, Namiki M, Inaki A, Taki J . Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Ann Nucl Med. 2013; 27(9):802-7. DOI: 10.1007/s12149-013-0749-x. View

16.

Even-Sapir E, Mishani E, Flusser G, Metser U . 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007; 37(6):462-9. DOI: 10.1053/j.semnuclmed.2007.07.002. View

17.

. Report of the task group on reference man. Ann ICRP. 2010; 3(1-4):iii. DOI: 10.1016/0146-6453(79)90123-4. View

18.

Anand A, Morris M, Larson S, Minarik D, Josefsson A, Helgstrand J . Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Res. 2016; 6(1):23. PMC: 4785173. DOI: 10.1186/s13550-016-0173-z. View

19.

Bastawrous S, Bhargava P, Behnia F, Djang D, Haseley D . Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice. Radiographics. 2014; 34(5):1295-316. DOI: 10.1148/rg.345130061. View

20.

Wondergem M, van der Zant F, van der Ploeg T, Knol R . A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013; 34(10):935-45. DOI: 10.1097/MNM.0b013e328364918a. View